4D Molecular Therapeutics Q2 FY26 net loss widens to $72.94 million; revenue rises to $3.78 million
FDMT•Q2 FY26 results
- 4D Molecular Therapeutics posted a Q2 2026 net loss of USD 72.94 million, widening from USD 54.66 million a year earlier.
- Revenue rose to USD 3.78 million from USD 15,000, driven by Otsuka clinical-trial cost sharing and reimbursements.
- R&D expense climbed to USD 68.28 million from USD 47.95 million, reflecting execution of 4D-150 Phase 3 trials in wet AMD.
Cash position and program timeline
- Cash, cash equivalents, and marketable securities totaled USD 430.63 million at June 30, down from USD 514.03 million at year-end 2025; runway seen into H2 2028.
- 4D-150 4FRONT-1 topline data is expected in Q2 2027; 4FRONT-2 topline data is expected in H2 2027, with a DME Phase 3 start targeted for Q3 2026.
Related News
Exxon oil output in Guyana down in May and June, government data shows
XOM•
Adial Pharmaceuticals CEO Cary Claiborne set to depart after Sept. 17 annual meeting; CDO Matthew Davidson slated to succeed
ADIL•
